<DOC>
	<DOCNO>NCT00032292</DOCNO>
	<brief_summary>The purpose Phase I/II , open-label , dose-escalation study evaluate investigational monoclonal antibody administer first-line therapy patient acute , Grade II , III , IV graft-versus-host disease ( GVHD ) . Patients eligible enrollment within 24 hour begin standard steroid treatment . The research conduct 10 clinical research sit US .</brief_summary>
	<brief_title>Research Study Visilizumab Treatment Acute Graft Versus Host Disease</brief_title>
	<detailed_description>A Phase I/II , open-label , dose-escalation pilot study design obtain preliminary safety , pharmacokinetic ( PK ) efficacy information visilizumab administer first-line therapy patient acute , Grade II , III , IV graft-versus-host disease ( GVHD ) . It anticipate 34 patient 10 study center could eligible enrollment study . Patients eligible enrollment within 24 hour begin standard steroid treatment ( 2 mg/kg methylprednisolone IV , 10 mg/kg hydrocortisone IV , per day ) . Steroids rapidly taper one week follow visilizumab administration .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Patients develop Grade II , III , IV acute GVHD follow allogeneic hematopoietic cell transplantation Patients receive GVHD prophylaxis include cyclosporine tacrolimus Clinical finding : skin thickening , joint contraction , oral ulceration , diarrhea . Patients onset date acute GVHD le equal 100 day posttransplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>